Advertisement

Topics

Aimmune Therapeutics Inc. Company Profile

18:02 EDT 19th June 2018 | BioPortfolio

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.


News Articles [822 Associated News Articles listed on BioPortfolio]

Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, ...

www.wallstequities.com/registration Aimmune Therapeutics Brisbane, Californiaheadquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of...

Jayson Dallas Leaves Ultragenyx for CEO Post at Aimmune

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: R...

Investors not nutty about Aimmune on digesting allergy data

An initial jump has been followed by a deeper drop in the share value of US biotech Aimmune Therapeutics…

Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy

BRISBANE, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food ...

Active-Investors: Wired News - Aimmune Therapeutics' Peanut Allergy Drug AR101 Met Primary Endpoint in Pivotal Phase-3 Clinical Trial

Stock Monitor: Cyanotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Aimmune Therapeutics, Inc. (NASDAQ: A...

BRIEF — Aimmune trading higher on full PALISADE publication

US biotech Aimmune Therapeutics has published full results from its 554-patient Phase III PALISADE trial…

DBV and Aimmune poised to dominate peanut allergy market

Last week, the top two contenders for first peanut allergy immunotherapy to market—DBV Technologies and Aimmune Therapeutics—presented to investors at...Read More... The post DBV and Aimmune poise...

Aimmune’s Peanut Allergy Drug Hits Study Goals, FDA Filing Planned

Peanuts rank among the top foods that spark allergic reactions, prompting schools to ban peanut butter sandwiches and travelers to decline airline snacks. Aimmune Therapeutics aims to help with a drug...

PubMed Articles [426 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1236 Associated Companies listed on BioPortfolio]

Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food a...

Aimmune Therapeutics Inc.

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensit...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Aimmune Therapeutics Inc." on BioPortfolio

We have published hundreds of Aimmune Therapeutics Inc. news stories on BioPortfolio along with dozens of Aimmune Therapeutics Inc. Clinical Trials and PubMed Articles about Aimmune Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aimmune Therapeutics Inc. Companies in our database. You can also find out about relevant Aimmune Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...


Corporate Database Quicklinks



Searches Linking to this Company Record